Shots:

• Scorpion to receive a $75M up front & is eligible to receive an additional option fee and milestones along with royalties on net sales of the product & will be responsible for the discovery and preclinical activities
• The collaboration combines Scorpion’s discovery platform with AstraZeneca’s leadership to develop and commercialize precision medicines for cancer treatment
• AstraZeneca gets an exclusive option to license global rights for three drug products & lead the development & commercialization activities globally. If AstraZeneca exercises three license options, Scorpion would obtain an option to co-develop and co-promote two programs in the US

Ref: AstraZeneca | Image: Biospace